Axogen EVP exercises options, sells 67,500 shares
Axogen, Inc. executive Marc A. Began, EVP & General Counsel, exercised 67,500 Employee Stock Options at an exercise price of $8.16 per share on August 10, 2026, receiving an equal number of common shares.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Axogen, Inc. executive Marc A. Began, EVP & General Counsel, exercised 67,500 Employee Stock Options at an exercise price of $8.16 per share on August 10, 2026, receiving an equal number of common shares. On the same date, he sold 67,500 common shares at a weighted average price of $47.345 per share in transactions executed pursuant to a Rule 10b5-1 trading plan adopted on March 11, 2026. Following the option exercise, 22,500 options from this grant remained outstanding, expiring on March 1, 2033, under a vesting schedule that completes on March 1, 2027.
Insider Trade Summary 10b5-1
Exercise and Sale: 67,500 shares ($2.64M approx. pre-tax spread)
Exercise and Sale
3 txns
Insider
Began Marc A
Role
EVP & General Counsel
Sold
67,500 shs ($3.20M)
Approx. gross sale proceeds
$3.20M
Approx. exercise cost
$551K
Approx. pre-tax spread
$2.64M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Employee Stock Option (right to buy) F3 | 67,500 | $0.00 | $0.00 |
| Exercise | Common Stock | 67,500 | $8.16 | $551K |
| Sale | Common Stock F1, F2 | 67,500 | $47.345 | $3.20M |
Holdings After Transaction:
Employee Stock Option (right to buy) — 22,500 contracts (Direct);
Common Stock — 50,135 shares (Direct)
Footnotes (3)
- F1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2026.
- F2. The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $47.16 to $47.72 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- F3. All shares of Axogen Inc. common stock underlying the stock option grant will be fully vested on March 1, 2027 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate stock options vest on March 1, 2025 (24 months from the grant date) and an additional 12.5% of the aggregate stock options vest each 6 months thereafter.
Key Figures
Options Exercised: 67,500 shares
Exercise Price: $8.16 per share
Shares Sold: 67,500 shares
+5 more
8 metrics
Options Exercised
67,500 shares
Employee Stock Options exercised on August 10, 2026
Exercise Price
$8.16 per share
Exercise or conversion price of Employee Stock Options
Shares Sold
67,500 shares
Common Stock sold on August 10, 2026
Weighted Average Sale Price
$47.345 per share
Weighted average price for multiple sale transactions
Sale Price Range
$47.16–$47.72 per share
Price range of individual sale transactions
Remaining Options
22,500 options
Total shares underlying options following the exercise
Option Expiration
March 1, 2033
Expiration date of the Employee Stock Option grant
10b5-1 Plan Adoption Date
March 11, 2026
Adoption date of Rule 10b5-1 trading plan governing the sales
Key Terms
Rule 10b5-1 trading plan, weighted average sale price, Employee Stock Option (right to buy), vesting schedule, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average sale price financial
"The reported price in Column 4 is a weighted average sale price."
Employee Stock Option (right to buy) financial
"security_title: Employee Stock Option (right to buy)"
vesting schedule financial
"based upon a vesting schedule whereby 50% of the aggregate stock options vest"
A vesting schedule is a timeline that determines when someone gains full ownership of certain benefits, such as company stock or retirement contributions. Think of it like earning the right to own a gift gradually over time, rather than receiving it all at once. It matters to investors because it affects when they can fully access or sell these benefits, influencing their financial planning and decision-making.
underlying the stock option grant financial
"All shares of Axogen Inc. common stock underlying the stock option grant"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Axogen (AXGN) executive Marc A. Began report in this Form 4?
Marc A. Began reported exercising 67,500 stock options at $8.16 per share and selling 67,500 common shares on August 10, 2026. The transactions involved Axogen common stock under an existing option grant.
At what prices did Marc A. Began’s Axogen (AXGN) transactions occur?
He exercised options at an $8.16 per-share exercise price and sold the resulting shares at a $47.345 weighted average price. The sale transactions occurred within a price range of $47.16 to $47.72 per share.
How many Axogen (AXGN) options does Marc A. Began retain from this grant?
After exercising 67,500 options, he held 22,500 options from this grant. These remaining options carry an $8.16 exercise price and an expiration date of March 1, 2033, subject to the disclosed vesting schedule.
What is the vesting schedule of Marc A. Began’s Axogen (AXGN) stock option grant?
The grant’s underlying Axogen common shares will be fully vested on March 1, 2027. According to the schedule, 50% vested on March 1, 2025, with an additional 12.5% vesting every six months thereafter until completion.
AI-generated analysis. How Rhea-AI works. Not financial advice.
